Barriers to Mohs Micrographic Surgery in Japanese Patients With Basal Cell Carcinoma.

IF 2.1 4区医学 Q3 DERMATOLOGY

Cutis Pub Date : 2024-07-01 DOI:10.12788/cutis.1057

Shuji Suzuki, Sang I Kim, Thomas K Barlow

引用次数: 0

Abstract

Mohs micrographic surgery (MMS) is a well-recognized treatment for nonmelanoma skin cancer worldwide, but Japan has lagged behind many other countries in adopting MMS. We present a series of 5 cases of MMS utilized in Japanese patients. All cases had a favorable outcome, each benefiting from MMS with a smaller final defect or a higher likelihood of cure than standard excision. Slow adaptation of MMS in Japan likely is due to a lack of familiarity with the technique, lack of a training pipeline for physicians, barriers to payment for the procedure, and misconceptions among Japanese physicians. Our case series demonstrates the utility of MMS in treating skin cancer among Japanese patients.

查看原文本刊更多论文

日本基底细胞癌患者接受莫氏显微手术的障碍。

莫氏显微放射手术（MMS）是世界公认的治疗非黑色素瘤皮肤癌的方法，但日本在采用 MMS 方面落后于许多其他国家。我们介绍了 5 例日本患者采用 MMS 的系列病例。所有病例均取得了良好的疗效，与标准切除术相比，MMS 的最终缺损更小，治愈的可能性更高。MMS 在日本的应用缓慢可能是由于对该技术缺乏了解、缺乏对医生的培训渠道、手术费用的支付障碍以及日本医生的误解。我们的病例系列证明了 MMS 在治疗日本患者皮肤癌方面的实用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cutis 医学-皮肤病学

CiteScore

1.10

自引率

0.00%

发文量

191

审稿时长

6-12 weeks

期刊介绍： Published since 1965, Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner. The journal is published monthly and focuses on concise clinical articles that present the practical side of dermatology. Referenced in Index Medicus/MEDLINE, it is respected and enjoyed by both specialists and derm-active generalists, enabling its readers to get what they need quickly and efficiently. Furthermore, Cutis is read by more physicians actively involved in the day-to-day treatment of dermatologic conditions than any other dermatology publication. Covering a broad range of pertinent and timely topics, Cutis is written and edited by industry leaders. For information on article submissions, please see our Information for Authors.